CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
July 22 2008 - 4:01PM
PR Newswire (US)
PALO ALTO, Calif., July 22 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) today announced that it will
release second quarter financial results for 2008 after the market
closes on Thursday, July 31, 2008. Company management will webcast
a conference call at 5:00 p.m. EDT, 2:00 p.m. PDT, on the company's
website. To access the live webcast, please log on to the Company's
website at http://www.cvt.com/ and go to the Investor Information
section. Alternatively, domestic callers may participate in the
conference call by dialing (866) 524-6241, and international
callers may participate in the conference call by dialing (706)
679-3061. Webcast and telephone replays of the conference call will
be available approximately two hours after the completion of the
call through Thursday, August 7, 2008. Domestic callers can access
the replay by dialing (800) 642-1687, and international callers can
access the replay by dialing (706) 645-9291; the PIN access number
is 56235490. About CV Therapeutics CV Therapeutics, Inc.,
headquartered in Palo Alto, California, is a biopharmaceutical
company primarily focused on applying molecular cardiology to the
discovery, development and commercialization of novel, small
molecule drugs for the treatment of cardiovascular diseases. CV
Therapeutics' approved products in the United States include
Ranexa(R) (ranolazine extended-release tablets), indicated for the
treatment of chronic angina in patients who have not achieved an
adequate response with other antianginal drugs, and Lexiscan(TM)
(regadenoson) injection for use as a pharmacologic stress agent in
radionuclide myocardial perfusion imaging in patients unable to
undergo adequate exercise stress. Ranolazine is approved for use in
the European Union as add-on therapy for the symptomatic treatment
of patients with stable angina pectoris who are inadequately
controlled or intolerant to first-line antianginal therapies.
DATASOURCE: CV Therapeutics, Inc. CONTACT: Investor and Media, John
Bluth, Executive Director, Corporate Communications & Investor
Relations, CV Therapeutics, Inc., +1-650-384-8850 Web site:
http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024